GlassScriptPhysician profile
Irum Qureshi
NPI 1306943857
$11,331.48
in general payments reported to CMS, 2019-2025
37 companies · $1,906 in 2025
The $1,906 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,367 · 2020: $959 · 2021: $1,497 · 2022: $1,843 · 2023: $1,954 · 2024: $1,805 · 2025: $1,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,533 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,532.89 |
| Education | $132.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,154.39 | 2019-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $2,036.97 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $1,095.31 | 2019-2025 | Hizentra, Andembry, Haegarda |
| Regeneron Healthcare Solutions, INC. | $944.55 | 2019-2025 | Dupixent |
| Genzyme Corporation | $706.51 | 2019-2025 | |
| Grifols USA, LLC | $678.73 | 2019-2025 | Xembify |
| Novartis Pharmaceuticals Corporation | $577.19 | 2020-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $559.90 | 2020-2025 | Cuvitru, Takhzyro |
| Optinose US, INC. | $417.14 | 2019-2023 | |
| Amgen INC. | $251.94 | 2022-2025 | Tezspire, Tavneos |
| Genentech USA, INC. | $196.77 | 2020-2024 | Xolair |
| Pfizer INC. | $194.41 | 2021-2025 | |
| Mylan Specialty L.P. | $155.01 | 2022-2024 | Yupelri |
| Shire North American Group INC | $146.28 | 2019 | |
| Bio Products Laboratory USA, INC. | $134.48 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $127.58 | 2019-2023 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.04 | 2020-2022 | |
| Abbvie INC. | $88.86 | 2022-2024 | |
| Blueprint Medicines Corporation | $85.81 | 2021-2024 | Ayvakit |
| Verona Pharma, INC. | $77.16 | 2025 | Ohtuvayre |
| Pharming Healthcare, INC. | $72.39 | 2022-2023 | Ruconest |
| Leo Pharma INC. | $59.39 | 2022-2025 | Anzupgo |
| Qol Medical, LLC | $57.55 | 2024 | Sucraid |
| Galderma Laboratories, L.P. | $50.00 | 2025 | Nemluvio |
| Viatris Specialty LLC | $49.73 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $44.60 | 2019-2023 | |
| Eyevance Pharmaceuticals LLC | $40.11 | 2021 | |
| Organon LLC | $34.11 | 2025 | |
| Octapharma USA, INC. | $29.47 | 2024 | Cutaquig |
| Gc Biopharma USA, INC. | $21.38 | 2025 | Alyglo |
| Incyte Corporation | $20.26 | 2021 | |
| Adma Biomanufacturing LLC | $19.58 | 2020 | |
| Aimmune Therapeutics, INC. | $19.08 | 2021 | |
| Biocryst US Sales Co., LLC | $18.16 | 2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $17.86 | 2020 | |
| Hikma Pharmaceuticals USA | $12.99 | 2023 | Ryaltris |
| Horizon Therapeutics Plc | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irum Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.